Sector News

UCB sheds speciality generics unit for $1.23bn

September 3, 2015
Life sciences

UCB is selling its speciality generics unit Kremers Urban Pharmaceuticals to US group Lannett for $1.23 billion.

The deal includes Kremers’ commercial portfolio of 18 products and 11 applications pending at the FDA, as well as its 381,000-square foot state-of-the-art manufacturing facility in Seymour, Indiana.

The Belgian drugmaker said it plans to use proceeds from the divestiture to cut debt and increase its capacity for strategic investments, to further accelerate growth and/or strengthen its innovative medicines pipeline.

With unanimous backing from both UCB’s and Lannett’s boards of directors, the deal and is expected to close in the fourth quarter of this year, subject to customary closing conditions.

Osteoporosis drug beats Lilly’s Forteo
Meanwhile, UCB and Amgen said clinical data show that their experimental bone-building drug romosozumab was better at improving hip bone mineral density in postmenopausal women with osteoporosis than Lilly’s Forteo (teriparatide).

In the Phase III trial, around 436 postmenopausal women at high risk of fractures were switched from treatment with bisphosphonates (such as Merck & Co’s Fosamax) to either romosozumab or Forteo for 12 months.

Specific data were not revealed at this time, but the companies said the trial met its primary endpoint, with their drug showing a statistically significant improvement in bone density compared to Forteo.

By Selina McKee

Source: Pharma Times

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend